An observational study in Artifical Inteligence, Cardiology and Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Abramson Cancer Center at Penn Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine — 11 open to participants now, 22 under way, none of them phase 3. Breast Neoplasms · Abramson Cancer Center at Penn Medicine.
Among the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine, this one has the largest planned enrollment of the 22 observational ones that give a count, is one of 3 that started in 2025, is one of 22 observational ones, reaches primary completion later than 15 of the 21 other live ones, and was the 65th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →11 of the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 11
First in 1998; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300,000 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 53 across the 45 interventional studies, 110 across the 22 observational. Of the 44 that completed or were terminated, 8 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
Abramson Cancer Center at Penn Medicine is the lead sponsor of 462 studies on the registry; 88 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.
5 of the studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06332131Abramson Cancer Center at Penn MedicineEffects of Immune Checkpoint Inhibitors on Coronary Microvasculature | 2026-11 |
| NCT03863457Abramson Cancer Center at Penn Medicine[18F] F-GLN by PET/CT in Breast Cancer | 2026-12 |
| NCT04841148Abramson Cancer Center at Penn MedicineAvelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer | 2027-07 |
| NCT03083288Abramson Cancer Center at Penn MedicineEvaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer | 2027-07 |
| NCT04855552Abramson Cancer Center at Penn MedicineTelehealth Weight Loss Program for Breast Cancer Survivors | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
While current AI technology is suitable for automating some repetitive clinical tasks, technical challenges remain in solving critical and gainful problems in the domains of patient and disease management. The proposed research seeks to address issues in medical AI, such as integrating medical knowledge effectively, making AI recommendations explainable to clinicians, and establishing safety guarantees.
The study will look at EMR data from cardiac, oncology, and patients at risk for acquiring sepsis.
Each group has clearly defined inclusion-exclusion criteria. For the machine learning model to predict ventricular arrhythmias and in-hospital cardiac arrest, we will construct patient cohorts consisting of adult (i.e., 18 years of age or older) patients admitted to Sickbay-accessible bed within a Penn Medicine hospital from 2020 to the present as well as patients identified as having experienced cardiac arrest using EHR records.
Inclusion Criteria:
Cardiology 18 years of age and older, admitted to any of the Penn Medicine hospitals from 2017 to the present. Sepsis 18 years of age at the time of presentation to an emergency department or admission to any Penn Medicine hospital from July 1, 2017, onward will be eligible as this represents the population at risk for acquiring sepsis Oncology 18 years of age and older with a diagnosis of invasive breast cancer (Stage 1-4) in the Penn Cancer registry
Exclusion Criteria All prediction models will exclude patients under the age of 18 from their patient data sets.
Cardiology Patients whose primary admission diagnosis was cardiac arrest Sepsis Those with pre-existing limitations on life-sustaining therapy will be excluded because their eligibility for sepsis definitions, care received, and outcomes, may be significantly and variably affected by pre-existing limitations on care. Oncology There are no other exclusions.
The primary objective in this clinical case scenario is to evaluate an ML model utilizing real-time cardiac telemetry, as well as other clinical, demographic, and imaging structured data sources, among hospitalized, intensive care unit (ICU) patients to predict impending inhospital cardiac arrest, identify potentially reversible causes of cardiac arrest, and predict which patients may have impending cardiac arrest due to shockable rhythms i.e. ventricular tachycardia (VT) or ventricular fibrillation (VF).
Other: AI-PERSONALIZED CLINICAL DECISION SUPPORT
The primary objective in this clinical case scenario is to evaluate an ML model utilizing structured and unstructured data from clinical, demographic, and tumor molecular and germline sequencing, among outpatients with cancer, to predict short-term mortality and/or symptom decline. The model for prediction to treatment response in breast cancer patients will be compared with two prognostic tools: 1) Conversation Connect, a previously validated machine learning mortality prediction tool that has been used at the University of Pennsylvania for routine clinical decision support, and 2) the Elixhauser Comorbidity Index, a comorbidity-based prognostic index used commonly in research and risk-adjustment.
Other: AI-PERSONALIZED CLINICAL DECISION SUPPORT
The primary objective in this clinical case scenario is to develop and evaluate an ML model that utilizes multidmodal clinical data (e.g., structured EHR data such as demographics, laboratory test results, and vital signs; unstructured EHR data including the text of clinical encounter notes and, where available, waveforms from real-time cardiac, hemodynamic, and respiratory monitoring devices) to predict the need for initiation of broad-spectrum antimicrobial therapy for hospitalized patients with sepsis. With a focus on implementable and explainable AI, we will produce well calibrated predictions that are also clinically meaningful at the bedside to aid real-time decision-making about diagnosis and treatment initiation. The model for timely diagnosis and intervention in sepsis will be compared with widely used commercial and open-source sepsis prediction models.
Other: AI-PERSONALIZED CLINICAL DECISION SUPPORT
AI-ENABLED DECISION MAKING FOR PERSONALIZED CLINICAL DECISION SUPPORT
Neurosymbolic Learning Algorithms
Develop and evaluate novel algorithms for training neurosymbolic models. We will develop data- and compute-efficient algorithms for end-to-end training of neurosymbolic models. This task will reduce the burden on clinician experts to provide fine-grained labels on voluminous EHR data.
Time frame: Prototype and develop new learning algorithms; 18 months. Benchmark and evaluate the learning algorithms; 24 months. Publish research results; 24 months
Explanation Methods
We will develop new explainable AI techniques that come with verifiable guarantees. These guarantees will enable trust and transparency in AI at a fundamental level.
Time frame: Prototype and develop new explanation algorithms; 18 months. Derive certified guarantees for explanations; 18 months. Benchmark and evaluate the explanation algorithms; 24 months. Extend certificates to new properties and tasks; 30 months. Publ
Methods for Safety Guarantees
We will develop new algorithms that can scalably extract complex logical rules governing safety within the data that have statistical guarantees. These techniques will be rooted in statistical analysis and assist users in identifying out of distribution data and detecting anomalies.
Time frame: Prototype and develop new rule learning algorithms; 30 months. Scale rule learning algorithms to larger data settings; 36 months. Incorporate new primitives to express complex rules; 36 months. Implement rule learning algorithms on baseline tasks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Nov 2028, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine →